Zenith Drugs Balance Sheet Health
Financial Health criteria checks 5/6
Zenith Drugs has a total shareholder equity of ₹623.3M and total debt of ₹246.4M, which brings its debt-to-equity ratio to 39.5%. Its total assets and total liabilities are ₹1.4B and ₹727.1M respectively. Zenith Drugs's EBIT is ₹156.1M making its interest coverage ratio 5.2. It has cash and short-term investments of ₹88.0M.
Key information
39.5%
Debt to equity ratio
₹246.39m
Debt
| Interest coverage ratio | 5.2x |
| Cash | ₹88.03m |
| Equity | ₹623.33m |
| Total liabilities | ₹727.05m |
| Total assets | ₹1.35b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: ZENITHDRUG's short term assets (₹1.1B) exceed its short term liabilities (₹641.5M).
Long Term Liabilities: ZENITHDRUG's short term assets (₹1.1B) exceed its long term liabilities (₹85.6M).
Debt to Equity History and Analysis
Debt Level: ZENITHDRUG's net debt to equity ratio (25.4%) is considered satisfactory.
Reducing Debt: ZENITHDRUG's debt to equity ratio has reduced from 296.4% to 39.5% over the past 5 years.
Debt Coverage: ZENITHDRUG's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ZENITHDRUG's interest payments on its debt are well covered by EBIT (5.2x coverage).